Extreme Networks saw its shares jump early on Thursday after the company announced that it will be acquiring the data center networking business from Broadcom following its acquisition of Brocade.
When gasoline prices are lower, Americans may be overpaying at the pump unless they pay attention to local price variations.
The top analyst upgrades, downgrades and initiations include ConocoPhillips, Goodyear Tire, Humana, Lululemon Athletica and Range Resources.
Camping World intends to offer 7 million shares in a secondary offering valued up to more than $253 million.
In a new research report, JPMorgan feels that owning the right gold stocks makes sense given the current global environment.
U.S. households continue to cut the cord to pay TV. More than 15 million households now pay only for broadband internet service.
Even with a pro-energy White House, things are far from perfect in the oil and gas sector. Now ConocoPhillips is delivering great news to its shareholders.
Raytheon has been one of the post-election winners that benefited from the so-called trump Bump due to higher military spending ambitions.
Lululemon Athletica Inc. (NASDAQ: LULU) reported its most recently quarterly earnings after the markets closed on Wednesday. The company posted $0.99 in earnings per share (EPS) and $789.9 million in revenue, versus consensus estimates…
March 29, 2017: The S&P 500 closed higher on the day, up 0.11 % and 2.56 points to 2,361.14. Separately the DJIA closed down 0.20% on the day at 20,659.39, down approximately 42.11 points.…
SCANA, Fang Holdings, Spirit Realty Capital, and Alliqua BioMedical all posted new 52-week lows Wednesday.
UnitedHealth, Cisco Systems, Travelers, and United Technologies weighed on the DJIA Wednesday.
With a new analyst coverage from Barclays' Ross Sandler, Amazon and Alphabet are given far stronger upside targets. Facebook's call looks more traditional in the upside.
A new academic paper estimates that job losses from adoption of robotic technology could change cost up to 6 million U.S. workers their jobs by 2025.
Vertex Pharmaceuticals shares were jumping after the firm released results from two Phase 3 studies in the treatment of cystic fibrosis in ages 12 and older.
